Novus Diagnostics
Developing ground-breaking diagnostics technologies that provide rapid answers right at the patient’s bedside
Developing ground-breaking diagnostics technologies that provide rapid answers right at the patient’s bedside
SepTec: Developing ground-breaking diagnostics technologies that provide rapid answers right at the patient’s bedside.
Novus Diagnostics, founded in 2020 and headquartered in Ireland, is dedicated to developing innovative diagnostics technologies to provide rapid answers at the patient's bedside. Their flagship product, SepTec, addresses the global challenge of sepsis, which claims over 11 million lives annually.
SepTec's technology combines novel electrochemical sensors, centrifugal microfluidics, and automated sample processing to diagnose and characterize bloodstream infections within 15 minutes, allowing for earlier targeted treatment and potentially saving lives.
The company recently secured a €5.00M Seed Round investment on 21 November 2022 from notable investors such as Enterprise Ireland, The European Innovation Council, and Grimpeur Holdings.
Novus Diagnostics operates in the Health Care industry and is positioned to make a significant impact on global health challenges. With a dedicated and driven team, the company is poised to drive meaningful change in the field of diagnostics and patient care.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €5.00M | 3 |
|
21 Nov 2022 |
| Grant | €2.40M | 1 |
|
12 Jan 2021 |
| Pre Seed Round | €40.00K | 1 | EIT Health | 02 Jun 2020 |
No recent news or press coverage available for Novus Diagnostics.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
